News
ARWR
34.46
+0.58%
0.20
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Is In A Strong Position To Grow Its Business
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Simply Wall St. · 06/16 12:36
ARWR, GDRX and ESPR among after hour movers.
Gainers: Inari Medical (NARI) +6%. Rhythm Pharmaceuticals (RYTM) +5%. Adaptive Biotechnologies (ADPT) +5%. The RealReal (REAL) +5%. Esperion Therapeutics (ESPR) +4%. Losers: GoodRx Holdings (GDRX) -6%. AlloVir (ALVR) -5%. Caribou Biosciences (CRBU)
Seekingalpha · 06/15 21:24
Baron Funds: “We Retain Conviction in Arrowhead (ARWR)”
Baron Funds, an asset management firm, published its “Baron Opportunity Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. Baron Opportunity Fund (the “Fund”) fell sharply and significantly lagged the broader market during t...
Insider Monkey · 06/14 11:42
Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences
PASADENA, Calif., June 07, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
Business Wire · 06/07 11:30
HC Wainwright Adjusts Price Target on Arrowhead Pharmaceuticals to $110 From $100, Reiterates Buy Rating
MT Newswires · 06/03 07:19
Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics
PASADENA, Calif., May 26, 2022--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is hosting a pulmonary research & development (R&D) Day today in New York City to discuss its emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candida...
Business Wire · 05/26 11:30
Where Arrowhead Pharmaceuticals Stands With Analysts
Within the last quarter, Arrowhead Pharmaceuticals (NASDAQ:ARWR) has observed the following analyst ratings:
Benzinga · 05/24 21:35
Goldman Sachs Adjusts Arrowhead Pharmaceuticals' Price Target to $66 from $90, Keeps Buy Rating
MT Newswires · 05/24 11:01
Catalyst Watch: JPMorgan event, Best Buy earnings and McDonald's drama
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 05/20 19:00
ARWR: Phase 3 PALISADE Study of ARO-APOC3 Underway…
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT
Benzinga · 05/16 17:32
--B. Riley Lowers Arrowhead Pharmaceuticals' PT to $82 from $106 to Account for Higher Research & Development Spend, Increased Cost of Capital; Keeps Buy Rating
MT Newswires · 05/13 09:56
Arrowhead Pharma down 12% despite quarterly beats, swing to net gain
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is down 12% in Wednesday afternoon trading despite reporting Q1 2022 results after the closing bell Tuesday that beat on the top and bottom lines. The company swung to
Seekingalpha · 05/11 18:12
--Piper Sandler Lowers Arrowhead Pharmaceuticals Price Target to $72 From $89, Maintains Overweight Rating
MT Newswires · 05/11 12:13
--Chardan Lowers Arrowhead Pharmaceuticals Price Target to $80 From $94, Maintains Buy Rating
MT Newswires · 05/11 11:19
--Baird Upgrades Arrowhead Pharmaceuticals to Outperform From Neutral, Cuts Price Target to $60 From $71
MT Newswires · 05/11 07:33
Arrowhead Pharmaceuticals: Q2 Earnings Insights
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q2 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 05/10 22:19
BRIEF-Arrowhead Pharmaceuticals Reports Qtrly Loss Per Share Of $0.41
reuters.com · 05/10 20:52
Arrowhead Pharmaceuticals GAAP EPS of $0.41 beats by $0.12, revenue of $151.8M beats by $29.65M
Arrowhead Pharmaceuticals press release (NASDAQ:ARWR): Q2 GAAP EPS of $0.41 beats by $0.12. Revenue of $151.8M (+362.7% Y/Y) beats by $29.65M.
Seekingalpha · 05/10 20:01
Arrowhead Pharmaceuticals Q2 EPS $0.41 Up From $(0.26) YoY, Sales $151.81M Beat $108.91M Estimate
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported quarterly earnings of $0.41 per share. This is a 257.69 percent increase over losses of $(0.26) per share from the same period last year. The company reported quarterly
Benzinga · 05/10 20:00
Arrowhead Pharmaceuticals Swings to Profit in Fiscal Q2 as Revenue Rises
MT Newswires · 05/10 16:28
More
Webull provides a variety of real-time ARWR stock news. You can receive the latest news about Arrowhead Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.